BioVersys AG | Finanzwire

BRIEF

published on 04/07/2026 at 07:05, 24 days 16 hours ago

BioVersys Announces 2026 Annual General Meeting of Shareholders

Board Elections Pharmaceutical Innovation Shareholder Registration BioVersys AGM 2026 Financial Statements 2025
PRESS RELEASE

published on 04/07/2026 at 07:00, 24 days 16 hours ago

BioVersys Issues Invitation to its 2026 Annual General Meeting of Shareholders
BioVersys issues invitation to its 2026 AGM, including key agenda items and election updates. Shareholders' participation details provided

Shareholders AGM Meeting 2026 BioVersys
BRIEF

published on 04/02/2026 at 07:05, 29 days 16 hours ago

BioVersys Names Anca Cighi as Head of Investor Relations

Investor Relations Biopharmaceutical BioVersys Anca Cighi Drug-resistant
PRESS RELEASE

published on 04/02/2026 at 07:00, 29 days 16 hours ago

BioVersys Appoints Anca Cighi as Head of Investor Relations and Communications
BioVersys AG appoints Anca Cighi as Head of Investor Relations and Communications. Anca brings 15 years of experience to the role

Investor Relations Communications BioVersys AG Antibacterial Products Anca Cighi
BRIEF

published on 03/31/2026 at 07:05, 1 month 1 day ago

BioVersys and Hackensack Meridian Health Collaborate on NTM Research

Collaboration BioVersys Ansamycin NTM Research Hackensack Meridian
PRESS RELEASE

published on 03/31/2026 at 07:00, 1 month 1 day ago

BioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian Health
BioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian Health

Collaboration BioVersys NTM Ansamycin Hackensack Meridian Health
BRIEF

published on 03/18/2026 at 07:05, 1 month 14 days ago

BioVersys Unveils 2025 Achievements and Financial Performance

Financial Results Clinical Trials BioVersys Antibacterial Drugs IPO Funding
PRESS RELEASE

published on 03/18/2026 at 07:00, 1 month 14 days ago

BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
BioVersys AG reports corporate highlights and financial results for the full year 2025, including significant progress in clinical and regulatory advancements of antibacterial products for MDR bacteria

Financial Results BioVersys AG Antibacterial Products Clinical Progress Regulatory Advancements
BRIEF

published on 03/16/2026 at 07:05, 1 month 16 days ago

BioVersys Gets FDA Nod for BV100 Phase 3 Trial for Pneumonia

FDA Approval Phase 3 Trial BV100 BioVersys CRAB Infections
PRESS RELEASE

published on 03/16/2026 at 07:00, 1 month 16 days ago

BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
BioVersys receives US FDA green light for BV100 HABP/VABP Phase 3 pivotal trial start to address CRABC infections in hospital-acquired bacterial pneumonia. A significant step in developing novel antibacterial products for MDR bacteria

Phase 3 BV100 BioVersys US FDA CRABC

Published on 05/01/2026 at 22:30, 1 hour 25 minutes ago

Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 22:30, 1 hour 25 minutes ago

Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 22:30, 1 hour 25 minutes ago

Apex Critical Metals Announces Extension of Marketing Agreement with Rumble Strip Media Inc.
Published on 05/01/2026 at 18:00, 5 hours 55 minutes ago

Star Copper to Present at the Emerging Growth Conference on May 7, 2026
Published on 05/01/2026 at 15:35, 8 hours 20 minutes ago

LNG Energy Group Announces Partial Revocation of Cease Trade Order and Proposed Private Placement

View all ACCESSWIRE

Published on 05/01/2026 at 19:23, 4 hours 32 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 18:40, 5 hours 15 minutes ago

Holding(s) in Company
Published on 05/01/2026 at 17:47, 6 hours 8 minutes ago

Key Figures 30.04.2026
Published on 05/01/2026 at 17:45, 6 hours 10 minutes ago

Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 6 hours 34 minutes ago

Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares

View all EQS

Published on 04/30/2026 at 20:00, 1 day 3 hours ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 4 hours ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 4 hours ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 5 hours ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 1 day 5 hours ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News